Table 4
Open in new tab

Cytokine-targeting antibodies in development for SLE: comparison and analysis

AntibodyAIN457UstekinumabTocilizumab
TargetIL17IL23 and IL12IL6 receptor
EfficiencyIndicated in patients with RAIndicated in patients with Crohn’s diseaseReduced SLENA, improved clinical indicators
SafetyIndicated in patients with RAIndicated in patients with Crohn’s diseaseMild to moderate AEs (increased incidence of mild infections).
Future prospectsDue to the proven significant role of IL17 and IL23 in the pathogenesis of SLE and the success of these antibodies in clinical trials studying the treatment of other autoimmune diseases, there is potential for the use of these antibodies for the treatment of SLE with preliminary clinical trials.High probability of conducting phase II and III clinical trials.
AntibodyAIN457UstekinumabTocilizumab
TargetIL17IL23 and IL12IL6 receptor
EfficiencyIndicated in patients with RAIndicated in patients with Crohn’s diseaseReduced SLENA, improved clinical indicators
SafetyIndicated in patients with RAIndicated in patients with Crohn’s diseaseMild to moderate AEs (increased incidence of mild infections).
Future prospectsDue to the proven significant role of IL17 and IL23 in the pathogenesis of SLE and the success of these antibodies in clinical trials studying the treatment of other autoimmune diseases, there is potential for the use of these antibodies for the treatment of SLE with preliminary clinical trials.High probability of conducting phase II and III clinical trials.
Table 4
Open in new tab

Cytokine-targeting antibodies in development for SLE: comparison and analysis

AntibodyAIN457UstekinumabTocilizumab
TargetIL17IL23 and IL12IL6 receptor
EfficiencyIndicated in patients with RAIndicated in patients with Crohn’s diseaseReduced SLENA, improved clinical indicators
SafetyIndicated in patients with RAIndicated in patients with Crohn’s diseaseMild to moderate AEs (increased incidence of mild infections).
Future prospectsDue to the proven significant role of IL17 and IL23 in the pathogenesis of SLE and the success of these antibodies in clinical trials studying the treatment of other autoimmune diseases, there is potential for the use of these antibodies for the treatment of SLE with preliminary clinical trials.High probability of conducting phase II and III clinical trials.
AntibodyAIN457UstekinumabTocilizumab
TargetIL17IL23 and IL12IL6 receptor
EfficiencyIndicated in patients with RAIndicated in patients with Crohn’s diseaseReduced SLENA, improved clinical indicators
SafetyIndicated in patients with RAIndicated in patients with Crohn’s diseaseMild to moderate AEs (increased incidence of mild infections).
Future prospectsDue to the proven significant role of IL17 and IL23 in the pathogenesis of SLE and the success of these antibodies in clinical trials studying the treatment of other autoimmune diseases, there is potential for the use of these antibodies for the treatment of SLE with preliminary clinical trials.High probability of conducting phase II and III clinical trials.
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close